EXPERIENCE OF USING THE ANTIBACTERIAL DRUG FOSFOMYCIN ESPARMA FOR THE TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the efficacy and safety of the antibacterial drug fosfomycin trometamol (Fosfomycin Esparma) in women of reproductive age with acute uncomplicated cystitis. Materials and methods. In order to assess the efficacy and safety of using fosfomycin trometamol (Fosfomycin Esparma), a prospective, non-randomized, uncontrolled study involving 32 women with acute uncomplicated cystitis was carried out. The average patients’ age was 27.3±3.1 years. Before the study, all women underwent a general clinical, bacteriological, and ultrasound examination. Inclusion criteria was the presence of pathognomonic symptoms of acute uncomplicated cystitis. Exclusion criteria were as following: complicated urinary tract infection, anatomical and functional disorders of the urinary tract, comorbidities. All patients were prescribed a study drug at a dose of 3 g, once. The efficiency of therapy was evaluated on days 3 and 14 after administration of Fosfomycin Esparma based on clinical and microbiological cure and safety. Results. The only bacterial pathogen isolated from the urine was E. coli. In 4 cases (12.5%) strains produced extended-spectrum β-lactamase. The sensitivity of E. coli to fosfomycin, piperacilfin/tazobactam, amikacin and meropenem was 100%. A resistance to ampicillin was 15.6%, compared to 9.4% for levofloxacin and norfloxacin and 12% for cefotaxime, ceftazidime, cefpoxin. By the 3rd day after receiving fosfomycin, the symptoms of cystitis were resolved in all patients. On day 14, according to the results of the urine culture, there was no growth of bacteria. During the follow-up period, no significant side effects was detected. Conclusion. Our study showed that antibacterial drug Fosfomycin Esparma in women of reproductive age with acute uncomplicated cystitis is effective and safe. Maintaining a high sensitivity to fosfomycin allows us to recommend this drug as an empirical antibiotic therapy in this cohort of patients.

Full Text

Restricted Access

About the authors

I. A Aboyan

MBUZ Clinical and diagnostic Center “Zdorovie”

Email: aboyan@center-zdorovie.ru
MD, professor Rostov-on-Don, Russia

Yu. N Orlov

MBUZ Clinical and diagnostic Center “Zdorovie”

Email: orlovurolog@gmail.com
urologist Rostov-on-Don, Russia

O. A Voloshina

MBUZ Clinical and diagnostic Center “Zdorovie”

Email: dr_voloshina@mail.ru
Ph.D., bacteriologist, Head of the Department of bacteriological studies of centralized laboratory Rostov-on-Don, Russia

N. V Orlov

CGSEN FKUZ “Medical Unit of Ministry of Internal Affairs of MVD of Russia in Rostov Region”

Email: dimm-rimm@mail.ru
epidemiologist Rostov-on-Don, Russia

D. S Pavlov

FGBOU VO Rostov State Medical University of the Ministry of Health of Russian Federation

5-year student Rostov-on-Don, Russia

References

  1. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653-660 doi: 10.1038/nrurol.2010.190.
  2. Schappert S.M., Rechtsteiner E.A. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011;(169):1-38.
  3. Loran O.B. Epidemiological aspects of urinary tract infections. Materials of the international symposium «Urinary tract infections in ambulatory patients». M. 1999:5-8.
  4. Rafalskiy V., Khodnevich L. Prevalence and risk factors of uncomplicated UTI: multicentre study sonar. Europ Urol Suppl. 2008;3(3): 267. doi: 10.1016/S1569- 9056(08)60781-2.
  5. Johansen T.E., Botto H., Cek M., et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011 ;38:64-70. Doi: 10.1016/j. ijantimicag.2011.09.009.
  6. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13. doi: 10.1016/j.idc.2013.09.003.
  7. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49:53-70. doi: 10.1067/mda.2003.7.
  8. Hooton T.M., Scholes D., Hughes J.P., et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335:468-474. doi: 10.1056/NEJM199608153350703.
  9. Scholes D., Hooton T.M., Roberts P.L., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142:20-27.
  10. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., et al. «DARMIS» research group. Current status of antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: Results of the «DARMIS» study (2010-2011). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2012;14(4):280-302.
  11. Naber K.G., Schito G., Botto H., et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54:1164-1175. doi: 10.1016/j.eururo.2008.05.010.
  12. Czaja C.A., Scholes D., Hooton T.M., et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45:273-280. doi: 10.1086/519268.
  13. Echols R.M., Tosiello R.L., Haverstock D.C., et al. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis. 1999 29:113-119. doi: 10.1086/520138.
  14. Urology. Russian clinical guidelines. Ed.: Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar. 2017;501 p.
  15. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21:1864. doi: 10.1016/S0149-2918(00)86734-X.
  16. Loran O.B. Chronic cystitis in women. Doctor. 1996;8: 6-9. Russian (Лоран О.Б. Хронический цистит у женщин. Врач. 1996;8:6-9).
  17. Hooton T.M. Recurrent urinary tract infection in women. Int. J. Antimicrob. Agents. 2001;17(4):259-268.
  18. EAU Guidelines, Urological Infections, https://uroweb.org/guideline/ urological-infections.
  19. Spellberg B., Guidos R., Gilbert D., et al. The Infectious Diseases Society of America The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;46:155-164 doi: 10.1086/524891.
  20. Alanis A.J. Resistance to Antibiotics: Are We in the Post-Antibiotic Era? Arch. Med. Res. 2005;36:697-705. doi: 10.1016/j.arcmed.2005.06.009.
  21. Laxminarayan R., Duse A., Wattal C., et al. Antibiotic resistance The need for global solutions. Lancet Infect. Dis. 2013;13:1057-1098. Doi: 10.1016/ S1473-3099(13)70318-9.
  22. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. World Health Organization; Geneva, Switzerland: 2014.
  23. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;48:1-12. doi: 10.1086/595011.
  24. ECDC. EMEA. The Bacterial Challenge: Time to React. Joint Technical Report. European Centre for Disease Prevention and Control; Stockholm, Sweden: European Medicines Agency; London, UK: 2009.
  25. Freire-Moran L., Aronsson B., Manz C., et al. The ECDC-EMA Working Group Critical shortage of new antibiotics in development against multidrug-resistant bacteria. Time to react is now. Drug Resist. Updates. 2011;14:118-124. doi: 10.1016/j.drup.2011.02.003.
  26. Bergen P.J., Landersdorfer C.B., Lee H.J., et al. «Old» antibiotics for emerging multidrug-resistant bacteria. Curr. Opin. Infect. Dis. 2012;25:626-633. doi: 10.1097/QCO.0b013e328358afe5.
  27. Bush K., Courvalin P., Dantas G., et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 2011;9:894-896. doi: 10.1038/nrmicro2693.
  28. Hendlin D., Stapley E.O., Jackson M., et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122-123.
  29. Popovic M., Steinort D., Pillai S., et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29(2):127-142. doi: 10.1007/s10096-009-0833-2.
  30. Skarzynski T., Mistry A., Wonacott A., et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure. 1996;4(12):1465- 1474. doi: 10.1016/S0969-2126(96)00153-0.
  31. Borisova M., Gisin J., Moyer C. Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb Drug Resist. 2014;20:231-237 doi: 10.1089/mdr.2014.0036.
  32. Falagas M.E., Vouloumanou E.K., Samonis G., et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-347. doi: 10.1128/CMR.00068-15.
  33. Kastoris A.C., Rafailidis P.I., Vouloumanou E.K., et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010;66:359-368. doi: 10.1007/s00228-010-0794-5.
  34. Anderson G.G., Kenney T.F., Macleod D.L., et al. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/ tobramycin antibiotic combination. Pathog Dis. 2013;67:39-45. doi: 10.1111/2049-632X.12015.
  35. Corvec S., Furustrand Tafin U., Betrisey B., et al. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57: 1421-1427. Doi: 10.1128/ AAC.01718-12.
  36. Mihailescu R., Furustrand Tafin U., Corvec S., et al. High activity of fosfomycin and rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014;58:2547-2553. Doi: 10.1128/ AAC.02420-12.
  37. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53:637-656. doi: 10.2165/00003495199753040-00007.
  38. Duez J.M., Mousson C., Siebor E., et al. Fosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infections. Clin Med Rev Ther. 2011;3:123-142. doi: 10.4137/CMRT.S5102.
  39. Roussos N., Karageorgopoulos D.E., Samonis G,. et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34:506-515. doi: 10.1016/j.ijantimicag.2009.08.013.
  40. Bergan T., Thorsteinsson S.B., Albini E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy. 1993;39:297-301. doi: 10.1159/000239140.
  41. Scaglione F., Cicchetti F., Demartini G., et al. Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt. Int J Clin Pharmacol Res. 1994;14:107-109.
  42. Qiao L.D., Zheng B., Chen S., et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157. doi: 10.1136/bmjopen-2013-004157.
  43. Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732-739. doi: 10.1016/j.ijid.2011.07.007.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media